tbuckley/cabot-search huggingface dataset:
SP0065 Inflammation and Skeletal Muscle: Potential Impact of Rheumatic Diseases on Muscle Function
Authors: H. Westerblad
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Muscle weakness and impaired work capacity are commonly observed symptoms in patients with rheumatic diseases. The degree of muscle impairment appears to depend on the severity of the disease and more than 50% reduction in muscle strength has been reported in patients with severe rheumatoid arthritis (RA). The decreased muscle strength is not only caused by a loss of muscle mass, but also by defective function within the skeletal muscle fibers. In fact, severe muscle weakness may occur even with a limited decrease in muscle mass. We have studied mechanisms underlying the defective muscle function in mice with collagen-induced arthritis (CIA), a mouse model that displays many pathological characteristics of human RA. Muscle fibers of CIA mice display impaired function of the contractile proteins as well as altered cellular calcium handling. These changes are accompanied by increased production reactive oxygen and nitrogen species, which results in major redox-induced protein modifications. <h3>Disclosure of Interest</h3> None Declared
AB0837-HPR Core stability exercises: in water or on land? comparison of the effects of two different core stabilization trainings
Authors: D. Bayraktar, A. Guclu-Gunduz, J. Lambeck, G. Yazici, S. Aykol, H. Demirci
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Core stabilization exercises have a theoretical basis and are used in the treatment of low back pain. But the effects of core stability exercises performed in water are unknown. <h3>Objectives</h3> To determine and compare the effects of Core stability exercise programs performed in different environments in low back pain (LBP) patients. <h3>Methods</h3> Twenty-three patients (47.78±13.20 years) and fifteen age-sex matched healthy controls (46.67±13.69) were included to the study. Patients were randomly divided into 2 groups as Core Stabilization (CS) or Water Specific Therapy (WST). Both groups underwent 8-weeks (3 times a week) core stabilization exercises in different environments. The assessments for pain, static endurance of trunk muscles, functional status and quality of life were performed before and after the treatment. <h3>Results</h3> Level of static endurance of trunk muscles was found lower in the patients compared to the controls at baseline (p&lt;0.05). Both groups showed significant improvements in all outcomes (p&lt;0.05) after 8-weeks intervention. When two groups were compared, no differences were found in the amount of change after the intervention (p&gt;0.05). After the treatment static endurance of trunk muscles of LBP patients became similar to controls (p&gt;0.05). <h3>Conclusions</h3> According to these results, core stabilization exercisetrainings performed on land or in water both could be beneficial in LBP patients and there is no difference between environments. <h3>References</h3> Hayden JA, van Tulder MW, MalmivaaraA et al. Exercise therapy for treatment of non-specific low back pain. <i>Cochrane Database Syst Rev</i> 2005 Jul 20;(3):CD000335. Waller B, Lambeck J, Daly D. Therapeutic aquatic exercise in the treatment of low back pain: a systematic review. <i>ClinRehabil</i> 2009 Jan;23(1): 3-14. Barr KP, Griggs M, Cadby T. Lumbar stabilization: core concepts and current literature, Part 1. <i>Am J Phys Med Rehabil</i> 2005 Jun;84(6):473-80. <h3>Disclosure of Interest</h3> None Declared
OS CALCIS BONE MINERAL MEASUREMENTS. AN EVALUATION OF THEIR CLINICAL UTILITY.
Authors: J. M. Vogel, P. D. Ross, R. D. Wasnich, A. John, U. C. Davis
Journal: Clinical Nuclear Medicine (1986)

Vogel, J. M.1; Ross, P. D.1; Wasnich, R. D.1; John, A.2; Davis, U. C.3 Author Information
AB0181 Glutamate as A Metabolic Biomarker for Monitoring Disease Activity of Systemic Lupus Erythematosus
Authors: J. Saegusa, Y. Irino, M. Yoshida, S. Tanaka, Y. Kogata, G. Kageyama, G. Tsuji, S. Kawano, S. Kumagai, A. Morinobu
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> "Omics" technologies, which include genomics, transcriptomics, proteomics, and metabolomics, are based on the comprehensive biochemical and molecular characterization of a biological sample. Among these, metabolomics has recently developed rapidly. Metabolomics, or metabolome analysis, is the comprehensive identification and quantification of all the low-molecular-weight metabolites in a biological sample. Because metabolism closely influences the organism9s phenotype, the characteristics of a disease are thought to more closely reflect alterations in the levels of metabolites than changes in gene or protein expression. Therefore, the examination of alterations in metabolite levels should help elucidate the physiological and pathological characteristics of diseases in more detail. Besides, cell metabolism is known to have a tremendous impact on the function of various immune cells. <h3>Objectives</h3> To identify novel metabolic biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE) by using gas chromatography/mass spectrometry (GC/MS). <h3>Methods</h3> Serum samples were obtained in the morning from fasting patients with SLE (n=26), rheumatoid arthritis (RA) (n=32), and healthy volunteers (n=26). Serum metabolite profiling was performed by GC/MS. The metabolic profiles of the patient and control groups were compared using multivariate statistical analysis. <h3>Results</h3> The levels of 25 metabolites were significantly different in SLE patients compared to healthy controls. The two-dimensional (2D) plot of the principal component analysis (PCA) scores showed a distinct clustering of the two groups. The corresponding 2D-PCA loadings plot and the 2D-scores plot for partial least squares-discriminant analysis (PLS-DA) loadings plot revealed that variations in the levels of glutamate, urea, tyrosine, phosphate and glycerol greatly contributed to the observed separation of the metabolite profiles of the SLE patients and healthy controls. In addition, there was a large difference in serum metabolite levels between SLE and RA, and a number of metabolites showed opposite changes between them. Furthermore, of 25 metabolites that were significantly changed in SLE, the serum level of glutamate was significantly correlated with the SLE disease activity index (SLEDAI) score and serum levels of C4 (Figure). <h3>Conclusions</h3> The pathogenesis of SLE may be accompanied by variations in the serum levels of low-molecular-weight metabolites, which supports the potential for using GC/MS-based metabolomics as a diagnostic and monitoring tool for SLE. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2294
Abstract 2282: Targeting oncogenic NDRG4: A promising strategy for meningioma treatment
Authors: Rama Prasadarao Kotipatruni, Xuan Ren, Robert Vanderwaal, Dinesh Kumar Thotala, Jerry Jaboin
Journal: Cancer Research (2012)

Abstract Meningiomas are the second most common brain tumors, and 20-30% of these tumors are aggressive. These aggressive subtypes are characterized by the capacity for invasion of normal brain with frequent and destructive recurrence patterns. Effective local therapies include surgery and radiation, but there is a need for novel molecular targets to improve survival and reduce morbidity for this group or cancer patients. We have recently identified the N-myc down regulated gene 4, NDRG4, protein as being overexpressed in aggressive meningioma, and have proposed to study its role in cell survival, invasion/migration and angiogenesis. We utilized shRNA-containing Lentiviral plasmids to downregulate NDRG4 mRNA and protein expression in two high grade meningioma cancer cell lines, IOMM-Lee and CH157MN. Downregulation resulted in reduction in cell survival, and G2-M cell cycle arrest. Utilizing DNA laddering and Annexin V/APC flow cytometry, we determined that the predominant form of cell death was apoptosis. NDRG4 downregulation also decreased cellular invasion and migration, as determined by a number of assays, including: spheroid migration, linear and radial wound healing assays, Boyden chamber matrigel invasion and 3D invasion assays. To determine the effect of NDRG4 depletion on angiogenesis, we utilized immortalized brain endothelial cells, bEnd.3 cells. We treated the bEnd.3 cells with conditioned media from the NDRG4 depleted IOMM-Lee and CH157MN cells, and the ability to form bEnd.3 capillary-like tubes, to proliferate and to invade was abrogated. NDRG4 is not overexpressed in bEnd.3 cells, and direct NDRG4 depletion had no effect on the cells. This study is significant as it is the first to demonstrate the role of NDRG4 in meningioma tumor biology. NDRG4 is involved in modulating cell proliferation, invasion, migration and angiogenesis in meningioma, and may play a valuable role as a molecular target in its treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2282. doi:1538-7445.AM2012-2282
Abstract 298: Breast cancer malignancy and drug sensitivity are regulated by mammaglobin 1.
Authors: Nadia Picot, Annie-Pier Beauregard, Roxann Guerette, Stéphanie Jean, Gilles A. Robichaud
Journal: Cancer Research (2013)

Abstract Breast cancer metastasis, a complex process enabling tumour cells dissemination, accounts for more than 90% of breast cancer mortality. The identification of genes involved in breast cancer metastasis is thus essential mitigate disease progression One of these factors, mammaglobin 1 (MGB1), is specifically expressed in mammary epithelial tissues and overexpressed in mammary cancers. Normally, MGB1 plays an essential role in cellular homeostasis. More recently, studies show that MGB1 is a useful biomarker for prognostic application and the detection of metastastatic breast cancer. However, no studies reveal the cellular and molecular function of MGB1 in this disease. We therefore set out to elucidate the role of MGB1 in breast cancer processes. We developed a breast cancer model with conditioned MGB1 expression to assess the molecular and cellular processes regulated by that protein which lead to breast cancer cell malignancy. After investigation, we observed that loss of MGB1 expression led to the reduction of cancer cell growth which was supported by the suppression of p38, JNK, ERK and NFκB activities. We also found that MGB1 promotes cell migration which is supported through increased activities of FAK and matrix metalloproteinases. MGB1 also seems to foster epithelial to mesenchymal transitioning of cancer cells via the activation of Snail, Twist and Zeb1 pathways. Interestingly, we also found that MGB1 confers breast cancer cell sensitivity to apoptosis and to various anti-cancer drug treatments. Our study provides the first in dept molecular elucidation of MGB1 function in breast cancer processes. In summary, it extends our knowledge on the biology of breast cancer malignancy and gives us new tools to achieve new therapeutic and diagnostic strategies against this disease. Citation Format: Nadia Picot, Annie-Pier Beauregard, Roxann Guerette, Stéphanie Jean, Gilles A. Robichaud. Breast cancer malignancy and drug sensitivity are regulated by mammaglobin 1. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 298. doi:10.1158/1538-7445.AM2013-298
THU0383 Is There A Difference between the Western and Eastern Turkish Familial Mediteranean Fever Patients?: Table 1.
Authors: I. Sari, D. Solmaz, P. Cetin, S. Ozturk, T. Basoglu, M. Tunca
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The prevalence of familial mediterranean fever (FMF) is relatively lower in western regions of Turkey compared with Eastern Anatolia. Likewise, the disease is quite uncommon in Greece and other Balkan countries. It is also presumed that patients from Eastern Anatolia have more severe phenotypic expression. If this presumption is relevant, underdetection of milder cases would contribute to observed distribution of FMF. <h3>Objectives</h3> To compare the clinical and genetical characteristics of our patients according to their ancesteral origins. <h3>Methods</h3> Among the 698 adult FMF patients registered in the computer files of our institute there were 214 cases whose ancestors were either strictly from Balkan countries and coastal regions of Eagean Sea (n=129) or Eastern Anatolia (n=85). Patients with mixed ancestors were not included. The following data were analyzed: age, disease duration, delay of diagnosis, genotype status, attacks despite colchicine, presence of fever, abdominal pain, pleuritic pain, arthritis, erysipelas-like erythema, amyloidosis and inflammatory back pain. <h3>Results</h3> Clinical features such as attacks despite colchicine, amyloidosis, protracted febrile myalgia, and delay in diagnosis were similar between the groups (table 1). Genotype analyses were available in 170 patients (76.9%). Four founder mutations (M694V, E148Q, V726A, M680I) were searched for every genotyped patient. 5.29% of the patients (n=9) were having wild type mutations. Allelic frequencies of the mutations were as follows: 46.8 for M694V, 13.8 for M680I, 10.6 for V726A, and 5.9 for E148Q. Comparison of the eastern and western patients revealed no difference between the groups according to the mutations (table 1). <h3>Conclusions</h3> The comparison of the western and eastern Turkish FMF patients revealed no statistically significant difference regarding to their clinical, demographical and genotype status. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2018
FACTOR XA INHIBITION BY RIVAROXABAN ATTENUATES CARDIAC REMODELING DUE TO HYPOXIC STRESS VIA PAR-2/ERK/NF-κB SIGNALING PATHWAY
Authors: Misa Azuma, Fumi Yoshimura, Shota Tanikawa, Shogo Hosako, Ryuji Kato, Yoshio Ijiri, Yasukatsu Izumi, Minoru Yoshiyama, Tetsuya Hayashi
Journal: Journal of the American College of Cardiology (2016)
Abstract 1530: Alveolar macrophage depletion decreases lung cytokines and decreases mouse lung tumor growth.
Authors: Jason Fritz, Meredith A. Tennis, Alvin Malkinson, Lori Dwyer-Nield
Journal: Cancer Research (2013)

Abstract While anti-inflammatory therapies are being evaluated in lung cancer, the role of specific immune effector cells and their products in lung carcinogenesis is unclear. Alveolar macrophage numbers increase as lung tumors progress, and subsequent changes in macrophage function are linked to increased growth factor production, accelerated tumor proliferation, enhanced angiogenesis, depressed immune response, and metastasis. However, the signaling molecules linking alveolar macrophages to advanced lung tumor growth are not well defined. To examine how macrophages drive lung tumorigenesis, clodronate-encapsulated liposomes were used to specifically deplete alveolar macrophages in mice bearing chemically-induced lung tumors. Treatment efficacy was assessed by evaluating tumor burden, multiplicity, proliferation index and histologic stage. Alveolar macrophage populations decreased to ≤ 50% of control levels during six weeks of liposomal clodronate treatment. This was associated with significantly decreased pulmonary levels of IGF-1, KC, IL-6 and CCL2. The concentrations of these cytokines strongly correlated with decreased macrophage numbers in lung lavage fluid. Tumor burden and Ki-67 index was reduced by 50% in clodronate-treated mice, corresponding with the 50% decrease in macrophage numbers and cytokine content. Therefore, macrophage depletion attenuates lung tumor proliferation in vivo, consistent with our previous observations linking macrophage IGF-1 production and lung tumor proliferation in vitro. These cytokines appear to mediate macrophage-stimulated lung tumorigenesis, and are thus potential therapeutic targets in lung cancer and chronic inflammatory lung disease. Citation Format: Jason Fritz, Meredith A. Tennis, Alvin Malkinson, Lori Dwyer-Nield. Alveolar macrophage depletion decreases lung cytokines and decreases mouse lung tumor growth. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1530. doi:10.1158/1538-7445.AM2013-1530
P135 Quality of Life and Adverse Effects in Patients Taking Pirfenidone For Idiopathic Pulmonary Fibrosis
Authors: J Capps, B Amies, A Duck, R Frank, C Leonard, J Holme
Journal: Thorax (2012)

<h3>Introduction and Objectives</h3> Pirfenidone is currently the only disease-modifying therapy for idiopathic pulmonary fibrosis. However the CAPACITY<sup>1</sup> study demonstrated frequent mild adverse effects. No data is available on the overall effect of pirfenidone on quality of life. Our aim was to describe patients’ experience of pirfenidone, taking these factors in to account. <h3>Methods</h3> This was a single-centre observational study of patients participating in the pirfenidone named patient programme. Participants completed the Self-Report Chronic Respiratory Disease Questionnaire (SR-CRQ), a quality of life assessment with four domains, at three monthly intervals. Adverse effects were also recorded. Patients were followed up until death or cessation of pirfenidone. <h3>Results</h3> 26 patients were included, with 9 patients reaching 3 months, 6 reaching 6 months, and 5 reaching 9 months during the study period. Mean age was 67±7 years, and 77% were male. There was a downward trend in all domains of the SR-CRQ, as illustrated in figure 1. However there were no significant differences in scores from baseline compared with individual time points. No relationship was found between SR-CRQ scores and adverse effects. Adverse effects were experienced by 14 patients (54%). These included gastrointestinal symptoms (n=12), photosensitivity (n=2) and fatigue (n=3). 5 patients stopped pirfenidone as a result of adverse effects. The mean weight in kilogrames of those patients experiencing adverse effects was lower than those who did not (72.5±12.7 vs 86.1±13.2, p=0.014). Age in years was higher in those with adverse effects (70±6 vs 64±8, p=0.035). Patients with more severe disease (FVC&lt;50%, DLCO &lt;35%) were also significantly more likely to have adverse effects (p=0.005). <h3>Conclusion</h3> The data from this study is limited due to small numbers, however we have not observed a significant change in quality of life from baseline in those treated with pirfenidone. Adverse effects were greater in older, lighter patients with more severe disease. Noble P, Albera C, Bradford W et al, for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–69.
P1065 EPIDEMIOLOGY OF HBV INFECTION IN A COHORT OF UGANDAN HIV-INFECTED PATIENTS AND RATE AND PATTERN OF LAMIVUDINE-RESISTANT HBV INFECTION IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
Authors: G. Calisti, R. Muhindo, Y. Boum, L.A. Wilson, G.M. Foster, A.M. Geretti, S. Bhagani
Journal: Journal of Hepatology (2014)
Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte‐rich B cell lymphoma
Authors: T Rüdiger, R D Gascoyne, E S Jaffe, D de Jong, J Delabie, C De Wolf-Peeters, S Poppema, L Xerri, C Gisselbrecht, S Wiedenmann, H K Müller-Hermelink
Journal: Annals of Oncology (2002)
AUDIT OF THE APPROPRIATENESS OF HEPATOMA SURVEILLANCE IN A COHORT OF PATIENTS ATTENDING A DEDICATED HAEMOCHROMATOSIS CLINIC
Authors: A Alakkari, Y Gammell, H O'Connor, D McNamara, N Breslin, B Ryan
Journal: Gut (2013)

<h3>Introduction</h3> Hereditary Haemochromatosis (HH) remains the commonest genetic disorder in populations of northern European origin with a prevalence of 1 per 220–250.<sup>1</sup> The HH service in Tallaght hospital is an expanding nurse delivered service. <h3>Aims/Background</h3> This audit reviews the service in terms of patient demographics, investigations and hepatocellular carcinoma (HCC) surveillance. <h3>Method</h3> Data was collected on patients attending the HH service in 2011 who underwent genetic testing. <h3>Results</h3> A total of 140 patients were identified; 107 (76%) were male and 33 (24%) female. Median age at diagnosis was 48 and 56 years, respectively. Their genetics were; 101 (74%) C282Y homozygote, 6 (4%) H63D homozygote, 20 (14%) compound heterozygote, 5 (3%) C282Y heterozygote, 2 (1%) H63D heterozygote and 6 (4%) had normal genetics. Mean ferritin and transferrin saturations at diagnosis were 980 µg/l and 75%, respectively. Liver function tests (LFTs) were abnormal at diagnosis in 93(66%) patients. Liver biopsy was performed on 45 patients according to established selection criteria for biopsy. Histology revealed mild fibrosis in 5 patients, bridging fibrosis in 4 and cirrhosis in 4. Patients received monitored weekly venesections as tolerated to achieve a target ferritin&lt;50 µg/l, followed by 3 monthly ferritin monitoring longterm. Patients with cirrhosis and advanced fibrosis were not receiving the recommended HCC surveillance as per AASLD guidelines.<sup>2 3</sup> <h3>Conclusion</h3> Appropriate HH management including HHC surveillance for cirrhotic patients and those with advanced fibrosis in accordance with AASLD guidelines requires close patient monitoring and long term follow up. A specialist dedicated nurse delivered service helps to provide this.
Abstract 783: High microsatellite instability predicts good prognosis in intestinal type gastric cancers
Authors: Meiying Song, Ji Yeong An, Sung Hoon Noh, Sung Kwan Shin, Yong Chan Lee, Hoguen Kim, Kim Hyunki
Journal: Cancer Research (2010)

Abstract A subset of gastric cancers shows high microsatellite instability (MSI-H). The reported clinicopathologic features of MSI-H gastric cancers are heterogeneous, and specific factors associated with prognosis have not been identified. We analyzed the clinicopathologic characteristics and prognostic factors in a large series (161 cases) of MSI-H gastric cancers, and compared the results to 315 cases of microsatellite stable or low MSI gastric cancers. The frequency of MSI-H gastric cancers was 9.0% (161/1786). MSI-H gastric cancers have distinct clinicopathologic features including female gender, older age, antral location, protruded gross type (Borrmann typeIand type II), well to moderate differentiation, intestinal type of Lauren classification, expanding type of Ming classification, non signet ring cell component, presence of mucinous component, moderate to severe lymphoid stromal reaction, and lower tumor stage. The MSI-H phenotype was associated with better prognosis (P = .044), and male gender (P = .035, HR: 0.23), intestinal/mixed type of Lauren classification (P &amp;lt;.001, HR: 0.09) and lower tumor stage (1 and 2) (P = .001, HR: 0.08) were independently favorable prognostic factors. With unique clinicopathologic features, the intestinal type MSI-H gastric cancers are associated with good prognosis and can be classified as a different subset of gastric cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 783.
1324 FAT DISTRIBUTION, LIPIDS AND INFLAMMATORY ACTIVITY CORRELATE WITH LIPID INFILTRATION OF THE LIVER IN OBESE/OVERWEIGHT CHILDREN
Authors: A. Wierzbicka-Rucinska, P. Socha, S. Chelstowska, D. Lebensztejn, E. Jurkiewicz, W. Janczyk, A. Niemirska, M. Litwin
Journal: Journal of Hepatology (2012)